AMPK-Pathway Target-Engagement Kit for Neurodegeneration Repurposing Trials

A central-lab biomarker service that measures whether a repurposed metabolic drug — metformin, resveratrol, or a SIRT1 activator — actually switches on the AMPK/SIRT1/PGC-1α cascade in a trial patient's blood, giving Alzheimer's and Parkinson's trial sponsors a go/no-go engagement endpoint.